Chronic Heart Failure — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for chronic heart failure. 573 active patents protecting 8 drugs from 6+ originators. First major cliff: 2031. Daily refresh.

8
Approved drugs
573
Active US patents
60/100
Avg vulnerability
$12.8B
Annual revenue covered

Originators in Chronic Heart Failure

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Boehringer Ingelheim 388 patents AstraZeneca 144 patents Generic (originally Searle/Pfizer) 21 patents Merck & Co. 18 patents Amgen 1 patents King Pfizer 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating chronic heart failure. Each bar = one year. Y-axis scaled to peak year (201 patents).

5
26
74
27
50
28
47
29
92
30
28
31
18
32
12
33
201
34
12
35
8
36
12
37
3
39
6
40
2
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Jardiance
empagliflozin
 Boehringer Ingelheim 388 64 $6.5B 2027-04-15
Farxiga
DAPAGLIFLOZIN
 AstraZeneca 144 64 $6.3B 2026-08-18
Verquvo
VERICIGUAT
 Merck & Co. 18 49 — 2031-05-19
Zestril
lisinopril
 Generic (originally Merck/AstraZeneca) 12 36 — 2035-11-06
Aldactone
spironolactone
 Generic (originally Searle/Pfizer) 8 50 — 2036-10-28
Corlanor
IVABRADINE
 Amgen 1 69 — 2026-12-12
Altace
RAMIPRIL
 King Pfizer 1 75 — 2039-08-16
Microzide
hydrochlorothiazide
 Generic (originally Merck) 1 75 — 2044-01-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11
12115179 Jardiance method of use 81 2030-02-11

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8420656 Verquvo composition of matter 10 2031-05-19
8420656 Verquvo composition of matter 10 2031-05-19
8420656 Verquvo composition of matter 10 2031-05-19
10736896 Verquvo composition of matter 10 2031-05-19
10736896 Verquvo composition of matter 10 2031-05-19
10736896 Verquvo composition of matter 10 2031-05-19
7919598 Farxiga composition of matter 10 2029-12-16
7919598 Farxiga composition of matter 10 2029-12-16
7919598 Farxiga composition of matter 10 2029-12-16
7919598 Farxiga composition of matter 10 2029-12-16

Related